Introducing GPRC5D and MonumenTAL-1 Trial for R/R Multiple Myeloma
July 16th 2025Panelists discuss the growing promise of GPRC5D-targeted therapy in relapsed/refractory multiple myeloma, highlighting MonumenTAL-1 trial data showing encouraging responses in heavily pretreated patients and emphasizing the importance of managing unique keratin-related and neurologic toxicities linked to GPRC5D expression.